HDAC

下级目录

Voruciclib
CUDC-101
SC-44463
Nanatinostat
L-Valine,N-(3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(Z)-2,3-dide hydro-2- aminobutanoyl-,ti-lactone, cyclic (1-2)-disulfide, (S-(E))-
TMP-269
Ricolinostat
MHY219
MPT0E028
PI3K/HDACInhibitor
BPR1J-340
LMK-235
ST7612AA1
MC1742
AN-7
Tubacin
5-Pyrimidinecarboxamide,N-hydroxy-2-[4-(2-naphthalenylsulfonyl)-1-piperazinyl]-(9CI)
Chidamide
Abexinostat
Resminostat [INN]
PXD-101
4SC-202
Pracinostat
(S)-HDAC-42 ， AR-42
SAHA
Apicidin
SPLITOMICIN
MS-275
Dacinostat
PCI-34051

目录项下的产品

1000023-04-0
1012054-59-9
104408-38-0
1235859-13-8
1235859-13-8 / MFCD335859138
Nanatinostat, also known as Tractinostat, CHR-3996 and VRx-3996, is an orally bioavailable, second-generation hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor CHR-3996 inhibits HDAC, resulting in an accumulation of highly acetylated histones, the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes; these events may result in the inhibition of tumor cell division and the induction of tumor cell apoptosis. This agent may upregulate HSP70 and downregulate anti-apoptotic Bcl-2 proteins more substantially than some first-generation HDAC inhibitors. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins.
128517-07-7
1314890-29-3
1316214-52-4
1326750-61-1
1326750-61-1 / MFCD426750611
MHY219 is a novel HDAC inhibitor. MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells. MHY219 was shown to enhance the cytotoxicity on DU145 cells (IC50, 0.36 μM) when compared with LNCaP (IC50, 0.97 μM) and PC3 cells (IC50, 5.12 μM). MHY219 showed a potent inhibition of total HDAC activity when compared with SAHA. MHY219 increased histone H3 hyperacetylation and reduced the expression of class I HDACs (1, 2 and 3) in prostate cancer cells. MHY219 effectively increased the sub-G1 fraction of cells through p21 and p27 dependent pathways in DU145 cells. MHY219 significantly induced a G2/M phase arrest in DU145 and PC3 cells and arrested the cell cycle at G0/G1 phase in LNCaP cells. Furthermore, MHY219 effectively increased apoptosis in DU145 and LNCaP cells, but not PC3 cells, according to Annexin V/PI staining and Western blot analysis. These results indicate that MHY219 is a potent HDAC inhibitor that targets regulating multiple asp
1338320-94-7
1339928-25-4
1395051-72-5
1418033-25-6
1428535-92-5
1776116-74-5
213262-83-0
537049-40-4
604769-01-9
604769-01-9 / MFCD04769019
R306465, also known as JNJ-16241199, is a novel hydroxamate-based histone deacetylase (HDAC) inhibitor with broad-spectrum antitumour activity against solid and haematological malignancies in preclinical models. R306465 was found to be a potent inhibitor of HDAC1 and -8 (class I) in vitro. R306465 potently inhibited cell proliferation of all main solid tumour indications, including ovarian, lung, colon, breast and prostate cancer cell lines, with IC50 values ranging from 30 to 300 nM. The high activity of R306465 in cell-based assays and in vivo after oral administration makes R306465 a promising novel antitumoral agent with potential applicability in a broad spectrum of human malignancies.
N-羟基-2-[4-(2-萘基磺酰基)-1-哌嗪基]-5-嘧啶甲酰胺
743420-02-2
783355-60-2
864814-88-0
866323-14-0
910462-43-0
929016-96-6
935881-37-1
149647-78-9
183506-66-3
5690-03-9
209783-80-2
404951-53-7
950762-95-5